John Crowley

64.6k total citations · 11 hit papers
341 papers, 28.4k citations indexed

About

John Crowley is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, John Crowley has authored 341 papers receiving a total of 28.4k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Hematology, 153 papers in Oncology and 141 papers in Molecular Biology. Recurrent topics in John Crowley's work include Multiple Myeloma Research and Treatments (162 papers), Protein Degradation and Inhibitors (71 papers) and Cancer Treatment and Pharmacology (66 papers). John Crowley is often cited by papers focused on Multiple Myeloma Research and Treatments (162 papers), Protein Degradation and Inhibitors (71 papers) and Cancer Treatment and Pharmacology (66 papers). John Crowley collaborates with scholars based in United States, United Kingdom and Japan. John Crowley's co-authors include Bart Barlogie, Kari Chansky, Ramón Rami–Porta, Dorothy J. Giroux, Peter Goldstraw, Elias Anaissie, Valerie W. Rusch, Frits van Rhee, Guido Tricot and John D. Shaughnessy and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

John Crowley

330 papers receiving 27.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

2007 2.9k citations John Crowley, Kari Chansky et al. Journal of Thoracic Oncology profile →
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

1999 2.0k citations Elias Anaissie, Madhav V. Dhodapkar et al. profile →
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

2001 923 citations John Crowley, Robert B. Livingston et al. Journal of Clinical Oncology profile →
The molecular classification of multiple myeloma

2006 783 citations Fenghuang Zhan, Joshua Epstein et al. Blood profile →
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000

2001 712 citations John Crowley et al. profile →
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006 532 citations Bart Barlogie, Guido Tricot et al. profile →
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

2015 530 citations John Crowley et al. Journal of Thoracic Oncology profile →
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

2002 507 citations Fenghuang Zhan, Maurizio Zangari et al. Blood profile →
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer

2007 482 citations John Crowley, Dorothy J. Giroux et al. Journal of Thoracic Oncology profile →
The International Association for the Study of Lung Cancer Lung Cancer Staging Project

2015 455 citations Kari Chansky, John Crowley et al. Journal of Thoracic Oncology profile →
Covariance Analysis of Heart Transplant Survival Data

1977 326 citations John Crowley et al. Journal of the American Statistical Association profile →

Peers

Countries citing papers authored by John Crowley

Since Specialization

Citations

This map shows the geographic impact of John Crowley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Crowley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Crowley more than expected).

Fields of papers citing papers by John Crowley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Crowley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Crowley. The network helps show where John Crowley may publish in the future.

Co-authorship network of co-authors of John Crowley

This figure shows the co-authorship network connecting the top 25 collaborators of John Crowley. A scholar is included among the top collaborators of John Crowley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Crowley. John Crowley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial 2024 ·Journal of Crohn s and Colitis ·Tim Raine, Silvio Danese, Stefan Schreiber, Xiang Gao, Stephen B. Hanauer, Joana Torres, Kristina Kligys, Xiu Huang, Ezequiel Neimark, (unknown), John Crowley, Raymond K. Cross	2
2	How Does the Pre-Registration Midwifery Programme Prepare the Newly Qualified Midwives for Their Post-Registration Perinatal Mental Health Role? A Mixed Methods Study 2024 ·Healthcare ·(unknown), Omorogieva Ojo, David Evans, John Crowley, (unknown), (unknown), (unknown)	0
3	Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design 2017 ·Clinical Cancer Research ·Shigeyuki Matsui, John Crowley	9
4	Curing myeloma at last: defining criteria and providing the evidence 2014 ·Blood ·Bart Barlogie, Alan Mitchell, Frits van Rhee, Joshua Epstein, Gareth J. Morgan, John Crowley	169
5	Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 2012 ·Clinical Cancer Research ·Christoph Heuck, Jackie Szymonifka, (unknown), John D. Shaughnessy, Saad Z. Usmani, Frits van Rhee, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, Clyde Bailey, Joshua Epstein, Antje Hoering, John Crowley, Bart Barlogie	13
6	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study 2011 ·Journal of Clinical Oncology ·Alberto S. Pappo, Shreyaskumar Patel, John Crowley, Denise K. Reinke, Klaus-Peter Kuenkele, Sant P. Chawla, Guy C. Toner, Robert G. Maki, Paul A. Meyers, Rashmi Chugh, Kristen N. Ganjoo, Scott M. Schuetze, Heribert Juergens, Michael Leahy, Birgit Geoerger, Robert S. Benjamin, Lee J. Helman, Laurence H. Baker	252
7	Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences 2010 ·Journal of Clinical Oncology ·Bart Barlogie, Michel Attal, John Crowley, Frits van Rhee, Jackie Szymonifka, Philippe Moreau, Brian G.M. Durie, Jean‐Luc Harousseau	103
8	International prognostic scoring system for Waldenström macroglobulinemia 2009 ·Blood ·Pierre Morel, Alain Duhamel, Paolo G. Gobbi, Meletios Α. Dimopoulos, Madhav V. Dhodapkar, Jason McCoy, John Crowley, Enrique M. Ocio, Ramón García‐Sánz, Steven P. Treon, Véronique Leblond, Robert A. Kyle, Bart Barlogie, Giampaolo Merlini	228
9	Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339) 2009 ·Journal of Thoracic Oncology ·Angela M. Davies, Kari Chansky, Primo N. Lara, Paul H. Gumerlock, John Crowley, Kathy S. Albain, (unknown), David R. Gandara	64
10	Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma 2008 ·Clinical Cancer Research ·Bart Burington, Bart Barlogie, Fenghuang Zhan, John Crowley, John D. Shaughnessy	35
11	Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling 2007 ·Clinical Cancer Research ·Jeffrey Haessler, John D. Shaughnessy, Fenghuang Zhan, John Crowley, Joshua Epstein, Frits van Rhee, Elias Anaissie, Mauricio Pineda‐Roman, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, Guido Tricot, Bart Barlogie	75
12	Induction chemoradiation and surgical resection for non–small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) 2001 ·Journal of Thoracic and Cardiovascular Surgery ·Valerie W. Rusch, Dorothy J. Giroux, Michael Kraut, John Crowley, Mark B. Hazuka, David H. Johnson, Melvyn Goldberg, Frank C. Detterbeck, Frances A. Shepherd, Ronald L. Burkes, Timothy Winton, Claude Deschamps, Robert B. Livingston, David Gandara	187
13	A southwest oncology group and cancer and leukemia group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in Adults with advanced osteosarcoma, ewing's sarcoma, and rhabdomyosarcoma 1998 ·Cancer ·(unknown), John Crowley, Stanley P. Balcerzak, Raymond A. Kempf, Raymond B. Weiss, Gerald H. Clamon, Laurence H. Baker	20
14	A southwest oncology group and cancer and leukemia group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in Adults with advanced osteosarcoma, ewing's sarcoma, and rhabdomyosarcoma 1998 ·Cancer ·Karen H. Antman, John Crowley, Stanley P. Balcerzak, Raymond A. Kempf, Raymond B. Weiss, Gerald H. Clamon, Laurence H. Baker	3
15	A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. 1998 ·PubMed ·Karen H. Antman, John Crowley, S P Balcerzak, Raymond A. Kempf, R B Weiss, Gerald H. Clamon, Laurence H. Baker	25
16	Long-term follow-up after high-dose therapy for high-risk multiple myeloma 1998 ·Bone ·Bart Barlogie, Sundar Jagannath, S. Naucke, S. Mattox, D Bracy, John Crowley, Guido Tricot, Raymond Alexanian	1
17	Discussion: Stephen George, a survey of monitoring practices in cancer clinical trials: Stephanie Green and John Crowley, data monitoring committees for Southwest Oncology Group clinical trials 1993 ·Statistics in Medicine ·Stephanie M. George, (unknown), John Crowley, S S Ellenberg, (unknown), Lyssa Friedman, Brown, Stuart Pocock, P. Armitage, R. Simon, Salim Yusuf, David Harrington, Peter B. Meier, Janet Wittes	2
18	Evaluation of amonafide in refractory and relapsing multiple myeloma 1991 ·Anti-Cancer Drugs ·(unknown), John Crowley, Sydney E. Salmon, (unknown), Thomas J. Braun, John D. Bonnet	3
19	A k -Sample Median Test for Censored Data 1982 ·Journal of the American Statistical Association ·Ron Brookmeyer, John Crowley	52
20	Reevaluation of the number of cells involved in the neutron induction of mammary neoplasms. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Michael N. Gould, Randy L. Jirtle, John Crowley, Kelly H. Clifton	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact